Ultragenyx Initiates New Development Program Studying KRN23 for the Treatment of Tumor-Induced Osteomalacia

News | 01. 06. 2015

Ultragenyx Pharmaceutical

NOVATO, Calif., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the initiation of a new development program for the human monoclonal anti-FGF23 antibody KRN23 (UX023) in tumor-induced osteomalacia (TIO). TIO results from typically benign tumors that produce excess levels of fibroblast growth factor 23 (FGF23), which can lead to severe osteomalacia, fractures, bone and muscle pain, and muscle weakness. Ultragenyx intends to initiate a Phase 2 study of KRN23 in six adult TIO patients in the first half of 2015.

KRN23 is being developed under a license and collaboration agreement between Ultragenyx and Kyowa Hakko Kirin Co., Ltd. KRN23 is being evaluated in a separate Phase 2 clinical study for pediatric patients with X-linked hypophosphatemia (XLH) and has completed multiple Phase 1/2 studies in adults with XLH.